Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thiogenesis Therapeutics Corp has secured a key European patent for its innovative thiol compounds, enhancing its global intellectual property portfolio. The patent supports the company’s lead compound, TTI-0102, which aims to combat oxidative stress, a factor in chronic diseases like mitochondrial disorders and diabetes.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.